参考文献:
1. EGFR–TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non–Small Cell Lung Cancer. JAMA Oncol. doi:10.1001/jamaoncol.2017.4526
2. Gainor, J.F., et al., EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis. Clin Cancer Res, 2016. 22(18).
3. Kato, S., et al., Hyper-progressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate. Clin Cancer Res, 2017.
4. Garassino MC, et al., Italian nivolumab expanded access program in nonsquamous non–small-cell lung cancer patients: results in never-smokers and EGFR-mutant patients, Journal of Thoracic Oncology (2018), doi: 10.1016/ j.jtho.2018.04.025.
5. Marina Chiara Garassino, et al., Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study,the lancet oncology,12 March 2018.
6. Strong PD-L1 expression predicts poor responseand de novo resistance to EGFR TKIs among non-small cell lung cancer patientswith EGFR mutation. J Thorac Oncol. 2018 Jul 26. pii: S1556-0864(18)30811-6. doi: 10.1016/j.jtho.2018.07.016.